Pacira BioSciences (PCRX)
(Delayed Data from NSDQ)
$16.57 USD
-0.03 (-0.18%)
Updated Nov 1, 2024 03:59 PM ET
After-Market: $16.58 +0.01 (0.06%) 7:58 PM ET
4-Sell of 5 4
A Value B Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$16.57 USD
-0.03 (-0.18%)
Updated Nov 1, 2024 03:59 PM ET
After-Market: $16.58 +0.01 (0.06%) 7:58 PM ET
4-Sell of 5 4
A Value B Growth C Momentum A VGM
Zacks News
Pacira Pharmaceuticals (PCRX) Soars: Stock Adds 12.9% in Session
by Zacks Equity Research
Pacira Pharmaceuticals (PCRX) was a big mover last session, as the company saw its shares rise more than 12% on Friday amid huge volumes.
Pacira Pharmaceuticals (PCRX) Down 4.7% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Pacira Pharmaceuticals (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Heron's Pain Candidate Meets Endpoint in Pivotal Studies
by Zacks Equity Research
Heron Therapeutics' (HRTX) pipeline candidate, HTX-011, meets primary endpoint in two pivotal phase III studies in bunionectomy and hernia repair.
Pacira (PCRX) Posts Earnings in Q4, Revenues in Line
by Zacks Equity Research
Pacira (PCRX) posted earnings in the fourth quarter of 2017 against the estimated loss but posted in line revenues in the quarter.
Implied Volatility Surging for Pacira (PCRX) Stock Options
by Zacks Equity Research
Pacira (PCRX) needs investors to pay close attention to the stock based on moves in the options market lately.
Pacira (PCRX) Up 9.3% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Pacira (PCRX) reported earnings more than 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pacira's Exparel sNDA to be Reviewed by FDA Advisory Committee
by Zacks Equity Research
Pacira (PCRX) announced that the FDA has asked for an Advisory Committee Meeting to review the supplemental New Drug Application for expanded indication of Exparel in the nerve block setting.
Pacira (PCRX) Posts Earnings in Q3, Revenues Lag Estimates
by Zacks Equity Research
Pacira's (PCRX) earnings surpassed estimates but sales missed the same in the third quarter of 2017. The company remains focused on the label expansion of Exparel.
Pacira Pharmaceuticals Focuses on Exparel's Label Expansion
by Zacks Equity Research
Pacira Pharmaceuticals, Inc. (PCRX) is making efforts to expand its flagship product, Exparel, which was launched in 2012.
Pacira (PCRX) Q2 Loss Wider than Expected, Revenues Miss
by Zacks Equity Research
Pacira Pharmaceuticals, Inc. (PCRX) remains confident about the prospects of its lead drug Exparel in Q2.
Why Is Pacira (PCRX) Down 4.5% Since the Last Earnings Report?
by Zacks Equity Research
Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pacira Focuses on Lead Candidate Exparel's Label Expansion
by Zacks Equity Research
We issued an updated report on Pacira Pharmaceuticals, Inc. (PCRX) on Apr 11.
Pacira (PCRX) Down 7.2% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Earnings Season Could Be Great for Pacira Pharmaceuticals (PCRX)
by Zacks Equity Research
Investors are always looking for stocks that are poised to beat at earnings season and Pacira Pharmaceuticals, Inc. (PCRX) may be one such company.
Conatus Pharmaceuticals (CNAT) Q4 Earnings: What's in Store?
by Zacks Equity Research
Conatus Pharmaceuticals Inc. (CNAT) is expected to report fourth-quarter 2016 results next month.
Adverum (ADVM) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Adverum Biotechnologies, Inc (ADVM) is expected to report fourth-quarter 2016 results on Mar 2.
Intrexon (XON): Will the Stock Pull a Surprise in Q4 Earnings?
by Zacks Equity Research
Intrexon Corporation (XON) is scheduled to report fourth-quarter 2016 results on Mar 1, after the market closes.
Agenus (AGEN): What's Ahead for the Stock in Q4 Earnings?
by Zacks Equity Research
Agenus Inc. (AGEN) is expected to report fourth-quarter 2016 results during this month.
Universal Health (UHS) Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Universal Health Services, Inc. (UHS) will release fourth-quarter 2016 results on Feb 28, after the market closes. Last quarter, the company posted a negative earnings surprise of 4.19%.
Puma Biotechnology (PBYI) Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Puma Biotechnology, Inc. (PBYI) is expected to report fourth-quarter 2016 results next month. The company has a mixed earnings history.
Arena Pharmaceuticals (ARNA) Q4 Earnings: What to Expect?
by Zacks Equity Research
Arena Pharmaceuticals, Inc. (ARNA) is expected to report fourth-quarter 2016 results next month.
Keryx (KERX) Q4 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Keryx Biopharmaceuticals, Inc. (KERX) is expected to report fourth-quarter 2016 results on Mar 1.
Tenet Healthcare (THC) Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Tenet Healthcare Corporation (THC) will release fourth-quarter 2016 results on Feb 27, after the market closes. Let's see how things are shaping up for this announcement.
Endocyte (ECYT) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Endocyte, Inc (ECYT) is expected to report fourth-quarter 2016 results on Mar 1. The company has an impressive track record, having beaten estimates on three of the trailing four quarters and reporting in-line results in the remaining quarter
Horizon (HZNP) Q4 Earnings: Stock Likely to Disappoint?
by Zacks Equity Research
Horizon Pharma plc (HZNP) is scheduled to report fourth-quarter 2016 results on Feb 27, before the opening bell.